Oric Pharmaceuticals (ORIC) vs Rigel Pharmaceuticals (RIGL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Rigel Pharmaceuticals (RIGL) has outperformed Oric Pharmaceuticals (ORIC) over the past year, losing 13.3% versus a loss of 36.7%. Over five years, RIGL leads with a +44.7% price change compared with -48.6% for ORIC. Oric Pharmaceuticals is the larger company by market cap ($764.9 million vs $754.9 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ORIC | RIGL |
|---|---|---|
| Share price | $7.36 | $40.09 |
| Market cap | $764.94M | $754.89M |
| 1-day change | -4.42% | -2.67% |
| YTD return | -10.02% | -6.40% |
| 1-year return | -36.66% | -13.26% |
| 5-year return | -48.64% | +44.73% |
| P/E ratio (TTM) | — | 2.49 |
| Forward P/E | — | 8.39 |
| EPS (TTM) | $-1.44 | $16.07 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $294.28M |
| Revenue growth (YoY) | — | +64.15% |
| Net income (latest FY) | $-129.47M | $367.02M |
| Gross margin | — | 93.33% |
| Operating margin | — | 42.63% |
| Net margin | — | 124.72% |
| 52-week high | $14.68 | $52.61 |
| 52-week low | $7.23 | $24.95 |
| Distance from 52-week high | -49.86% | -23.80% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +194.97% | +60.64% |
| Average volume | 1.59M | 248.06K |
| Shares outstanding | 103.93M | 18.83M |
| Employees | 111 | 172 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- RIGL has outperformed ORIC by 23.4 percentage points over the past year.
About Oric Pharmaceuticals
ORIC stock →ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies to counter the resistance mechanisms in cancers in the United States. Its clinical stage product candidates include enozertinib formerly known as ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, that selectively target epidermal growth factor receptor (EGFR) exon 20 and human epidermal growth factor receptor 2 exon 20 with high potency towards exon 20 insertion mutations; and rinzimetostat formerly known as ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study.
Health Care · Biotechnology: Pharmaceutical Preparations · 111 employees
About Rigel Pharmaceuticals
RIGL stock →Rigel Pharmaceuticals, Inc., a biotechnology company, develops and provides therapies that enhance the lives of patients with hematologic disorders and cancer in the United States. The company offers TAVALISSE, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; REZLIDHIA, a non-intensive monotherapy to treat adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC), as well as to treat adult and pediatric patients twelve years of age and older with advanced or metastatic RET fusion-positive thyroid cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 172 employees
ORIC vs RIGL FAQ
Which is bigger, Oric Pharmaceuticals or Rigel Pharmaceuticals?
Oric Pharmaceuticals (ORIC) is larger, with a market capitalization of $764.94M compared with $754.89M for Rigel Pharmaceuticals (RIGL).
Which stock has performed better over the past year, ORIC or RIGL?
RIGL returned -13.26% over the past 12 months, compared with -36.66% for ORIC (price return, excluding dividends). Past performance does not predict future results.
Are Oric Pharmaceuticals and Rigel Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.